|
|
Volumn 150, Issue 2, 2010, Pages 287-
|
|
Bevacizumab vs ranibizumab for age-related macular degeneration: Early results of a prospective double-masked, randomized clinical trial
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
RANIBIZUMAB;
ANGIOGENESIS INHIBITOR;
MONOCLONAL ANTIBODY;
VASCULOTROPIN A;
CLINICAL TRIAL;
DRUG EFFICACY;
HUMAN;
LETTER;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RETINA MACULA AGE RELATED DEGENERATION;
VISUAL ACUITY;
COMPARATIVE STUDY;
DOUBLE BLIND PROCEDURE;
DRUG ANTAGONISM;
EXUDATIVE MACULAR DEGENERATION;
INJECTION;
METHODOLOGY;
NOTE;
OPTICAL COHERENCE TOMOGRAPHY;
PATHOLOGY;
PATHOPHYSIOLOGY;
PHYSIOLOGY;
PUBLIC HOSPITAL;
RANDOMIZED CONTROLLED TRIAL;
RETINA;
TREATMENT OUTCOME;
VITREOUS BODY;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
DOUBLE-BLIND METHOD;
HOSPITALS, VETERANS;
HUMANS;
INJECTIONS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RESEARCH DESIGN;
RETINA;
TOMOGRAPHY, OPTICAL COHERENCE;
TREATMENT OUTCOME;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
VISUAL ACUITY;
VITREOUS BODY;
WET MACULAR DEGENERATION;
|
|
EID: 77955506858
PISSN: 00029394
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ajo.2010.04.006 Document Type: Letter |
|
Times cited : (5)
|
|
References (1)
|
